Clinical trials
catalyst calendar across sponsors →Studies where KROS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 13 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., +8 more) · FINRA short interest 5.9 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 4 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyNCT07704099Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: KER-065 | Duchenne Muscular Dystrophy | 36 | 2029-07-17 | in 1,063 d | 2026-08-10 |
| A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).NCT05927012Percentage of participants experiencing Treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally. | Drug: KER-047 | Iron Deficiency Anemia | 0 | 2025-08-29 | — | 2023-11-24 |
| A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).NCT05975905results2026-07-02Change From Baseline in PVR (Pulmonary Vascular Resistance)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was voluntarily terminated early, following a safety review and observation of pericardial effusions. | Biological: Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Pulmonary Arterial Hypertension | 113 | 2025-03-05actual | — | 2026-07-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19